Antiviral Inactivated Vaccines: Looking to the Past to Face the Future—A Narrative Review

Throughout human history, contagious infectious diseases have significantly impacted societies, shaping the fate of great dynasties and challenging economic and political systems, social relations, and the overall well-being of the human species. The SARS-CoV-2 pandemic brought unprecedented challenges, emerging in the context of extreme globalization and rapid technological development. The speed of viral spread, the highest absolute mortality rate caused by a viral agent in the last 100 years, and the severe economic and social consequences imposed an urgent need for vaccine development on a previously unimaginable timescale. The proven safety and efficacy of inactivated vaccines enabled the development and large-scale application of the first immunizer against SARS-CoV-2 in less than a year after the World Health Organization (WHO) declared the pandemic. In this review, we discuss the importance of inactivated antiviral vaccines and their historical impact in containing highly harmful diseases affecting humanity. We also explore the cellular mechanisms by which inactivated vaccines may induce immunogenic responses against viral pathogens. In addition, we bring to light a discussion about a fast, cost-effective, potentially efficient technology for large-scale immunizer production: High hydrostatic pressure (HHP), a method long supported by decades of preclinical studies and which is especially effective in the context of enveloped viruses. Finally, we discuss the role of inactivated antiviral vaccines in the face of advances in biotechnology and, therefore, the emergence of vaccines that use genetic engineering in their production, such as RNA, DNA and viral vaccines, which have gained special prominence during the COVID-19 pandemic.

• Publication year

  2025

• Venue

  Vaccines

• Publication date

  2025-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/vaccines13111140PMID 41295513PMCID 12656770
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of influenza vaccines and its relationship with immunological surrogate endpoints: a systematic review and meta-analysis of RCT.

  2025cited by this paper
• Production and Immune Response Against Pandemic Influenza Candidate Vaccines as Preparedness Against the Circulating H5N1 Influenza Viruses

  2025cited by this paper
• Development and in vivo evaluation of a SARS-CoV-2 inactivated vaccine using high hydrostatic pressure

  2025influential reference
• Public health, war and cross-border challenges: the recent cVDPV2 polio outbreak in Gaza

  2025cited by this paper
• Poliomyelitis in Nigeria: Impact of Vaccination Services and Polio Intervention and Eradication Efforts

  2025cited by this paper
• Distinct Adverse Reactions to mRNA, Inactivated Virus, and Adenovirus Vector COVID-19 Vaccines: Insights from a Cohort Study on Atopic and Non-Atopic Subjects in Brazil

  2024cited by this paper
• Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination.

  2024cited by this paper
• Adjuvants in COVID-19 vaccines: innocent bystanders or culpable abettors for stirring up COVID-heart syndrome

  2024cited by this paper
• DNA Vaccines: Their Formulations, Engineering and Delivery

  2024cited by this paper
• Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status

  2023cited by this paper
• Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials

  2023cited by this paper
• Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population

  2023cited by this paper
• Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence

  2023cited by this paper
• The 1889-90 flu pandemic in Greece: a social, cultural and economic history with lessons for the 21st century.

  2023cited by this paper
• Review of adverse events associated with COVID-19 vaccines, highlighting their frequencies and reported cases

  2023cited by this paper
• SARS-CoV-2-specific T cell responses wane profoundly in convalescent individuals 10 months after primary infection

  2023cited by this paper
• Impact of Processing Method and Storage Time on Phytochemical Concentrations in an Antioxidant-Rich Food Mixture

  2023cited by this paper
• The development of DNA vaccines against SARS-CoV-2

  2023cited by this paper
• Transmission Characteristics and Inactivated Vaccine Effectiveness Against Transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China

  2023cited by this paper
• Short-Term Adverse Effects Following Booster Dose of Inactivated-Virus vs. Adenoviral-Vector COVID-19 Vaccines in Algeria: A Cross-Sectional Study of the General Population

  2022cited by this paper
• mRNA COVID-19 Vaccines—Facts and Hypotheses on Fragmentation and Encapsulation

  2022cited by this paper
• The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case

  2022cited by this paper
• Adverse events after administration of the first and second doses of messenger RNA-based COVID-19 vaccines in Japanese subjects aged 12–18 years

  2022cited by this paper
• Safety and Adverse Events Related to Inactivated COVID-19 Vaccines and Novavax;a Systematic Review

  2022cited by this paper
• Intradermal Immunization of SARS-CoV-2 Original Strain Trimeric Spike Protein Associated to CpG and AddaS03 Adjuvants, but Not MPL, Provide Strong Humoral and Cellular Response in Mice

  2022cited by this paper
• Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects

  2022cited by this paper
• Viral Vector Vaccine Development and Application during the COVID-19 Pandemic

  2022cited by this paper
• Coronavirus as the Possible Causative Agent of the 1889–1894 Pandemic

  2022cited by this paper
• Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India

  2022cited by this paper
• Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes

  2022cited by this paper
• COVID-19, Vaccines, and Thrombotic Events: A Narrative Review

  2022cited by this paper
• Life and death of smallpox.

  2022cited by this paper
• Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.

  2022cited by this paper
• COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.

  2021cited by this paper
• Pandemics Throughout History

  2021cited by this paper
• Autoimmune hepatitis after SARS-CoV-2 vaccine: New-onset or flare-up?

  2021cited by this paper
• Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum

  2021cited by this paper
• DNA vaccines for SARS-CoV-2: toward third-generation vaccination era

  2021cited by this paper
• An Overview of Influenza Viruses and Vaccines

  2021cited by this paper
• COVID-19 Vaccine in Pregnant and Lactating Women: A Review of Existing Evidence and Practice Guidelines

  2021cited by this paper
• Time of day influences immune response to an inactivated vaccine against SARS-CoV-2

  2021cited by this paper
• Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial

  2021cited by this paper
• SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients

  2021cited by this paper
• Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19

  2021cited by this paper
• Clinical evidence that the pandemic from 1889 to 1891 commonly called the Russian flu might have been an earlier coronavirus pandemic

  2021cited by this paper
• Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

  2021cited by this paper
• COVID-19 Vaccine Considerations during Pregnancy and Lactation

  2021cited by this paper
• US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.

  2021cited by this paper
• Strategies for Vaccination: Conventional Vaccine Approaches Versus New-Generation Strategies in Combination with Adjuvants

  2021cited by this paper
• Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

  2021cited by this paper
• Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques

  2021cited by this paper
• Viral hepatitis C pandemic: Challenges and threats to its elimination

  2021cited by this paper
• Development of an inactivated vaccine candidate for SARS-CoV-2

  2020influential reference
• Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial

  2020cited by this paper
• Rapid COVID-19 vaccine development

  2020cited by this paper
• Fifty Years of Influenza A(H3N2) Following the Pandemic of 1968.

  2020cited by this paper
• SARS-CoV-2 vaccines in development

  2020cited by this paper
• Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

  2020cited by this paper
• The Justinianic Plague: An inconsequential pandemic?

  2019cited by this paper
• The 1918 influenza pandemic: 100 years of questions answered and unanswered

  2019cited by this paper
• Avian influenza viruses in humans: lessons from past outbreaks.

  2019cited by this paper
• The safety of inactivated influenza vaccines in pregnancy for birth outcomes: a systematic review

  2018cited by this paper
• mRNA vaccines — a new era in vaccinology

  2018cited by this paper
• Th1 memory differentiates recombinant from live herpes zoster vaccines

  2018cited by this paper
• Engineering DNA vaccines against infectious diseases

  2018cited by this paper
• Influenza

  2018cited by this paper
• The immunogenicity of GSK’s recombinant hepatitis B vaccine in children: a systematic review of 30 years of experience

  2017cited by this paper
• Stability of different influenza subtypes: How can high hydrostatic pressure be a useful tool for vaccine development?

  2017cited by this paper
• Global Mortality Impact of the 1957–1959 Influenza Pandemic

  2016cited by this paper
• Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs

  2015cited by this paper
• Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).

  2015cited by this paper
• Psoralen Inactivation of Viruses: A Process for the Safe Manipulation of Viral Antigen and Nucleic Acid

  2015cited by this paper
• The consequences of human actions on risks for infectious diseases: a review

  2015cited by this paper
• Evolutionary reversion of live viral vaccines: Can genetic engineering subdue it?

  2015cited by this paper
• Intranasal Immunization with Pressure Inactivated Avian Influenza Elicits Cellular and Humoral Responses in Mice

  2015influential reference
• mRNA-based therapeutics — developing a new class of drugs

  2014cited by this paper
• Genesis and pathogenesis of the 1918 pandemic H1N1 influenza A virus

  2014cited by this paper
• High-pressure chemical biology and biotechnology.

  2014cited by this paper
• Developments in Viral Vector-Based Vaccines

  2014cited by this paper
• History of vaccination

  2014cited by this paper
• Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden.

  2014cited by this paper
• Efficacy of high-dose versus standard-dose influenza vaccine in older adults.

  2014cited by this paper
• Full Inactivation of Human Influenza Virus by High Hydrostatic Pressure Preserves Virus Structure and Membrane Fusion While Conferring Protection to Mice against Infection

  2013cited by this paper
• Pre-existing immunity against vaccine vectors – friend or foe?

  2013cited by this paper
• DNA vaccines: roles against diseases.

  2013cited by this paper
• Development of a new hydrogen peroxide–based vaccine platform

  2012cited by this paper
• Vaccination of immunocompromised patients.

  2012influential reference
• Fundamentals of Vaccine Immunology

  2011cited by this paper
• Immunization with 1976 swine H1N1‐ or 2009 pandemic H1N1‐inactivated vaccines protects mice from a lethal 1918 influenza infection

  2011cited by this paper
• Evolution of new variants of Vibrio cholerae O1.

  2010cited by this paper
• The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults

  2010cited by this paper
• Lessons from the Salk Polio Vaccine: Methods for and Risks of Rapid Translation

  2010cited by this paper
• Transmissibility and geographic spread of the 1889 influenza pandemic

  2010cited by this paper
• Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines

  2009cited by this paper
• Effects of hydrostatic pressure on the stability and thermostability of poliovirus: a new method for vaccine preservation.

  2009cited by this paper
• Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.

  2008cited by this paper
• The history and challenge of HIV prevention.

  2008cited by this paper
• The fusogenic state of mayaro virus induced by low pH and by hydrostatic pressure

  2007cited by this paper
• Global polio eradication initiative.

  2006cited by this paper
• The history of smallpox.

  2006cited by this paper

• Dose-Dependent Efficacy of a Riboflavin and Ultraviolet Light-Inactivated Whole-Virion SARS-CoV-2 Vaccine in a Hamster Infection Challenge Model.

  2026cites this paper